A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 3 Recruiting
400 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
OLYMPIA-5
Phase 3 Recruiting
470 enrolled
FIERCE-HN
Phase 3 Recruiting
410 enrolled
IMPACT-AML
Phase 3 Recruiting
339 enrolled
TERZO
Phase 3 Recruiting
124 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
LUTEON
Phase 3 Recruiting
40 enrolled
SUCCESSOR-1
Phase 3 Recruiting
810 enrolled
EVER
Phase 3 Recruiting
540 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
MEVPRO-1
Phase 3 Recruiting
600 enrolled
RAINFOL-03
Phase 3 Recruiting
544 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
228 enrolled
Magic-C002
Phase 3 Recruiting
446 enrolled
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3 Recruiting
390 enrolled
PRIME
Phase 3 Recruiting
1,204 enrolled
FREEDOM
Phase 3 Recruiting
318 enrolled
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3 Recruiting
50 enrolled
CHIPRO
Phase 3 Recruiting
454 enrolled
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
Phase 3 Recruiting
1,199 enrolled
COLLISION RELAPSE Trial
Phase 3 Recruiting
360 enrolled
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3 Recruiting
218 enrolled
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Phase 3 Recruiting
300 enrolled